A lawsuit was filed on behalf of investors in Revance Therapeutics Inc (NASDAQ:RVNC) shares over alleged securities laws violations and NASDAQ:RVNC investors should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/22/2015 --An investor, who purchased shares of Revance Therapeutics Inc (NASDAQ:RVNC), filed a lawsuit over alleged violations of Federal Securities Laws by Revance Therapeutics regarding certain allegedly false and misleading statements made in connection with Revance Therapeutics' June 19, 2014 follow-on public stock offering.

Investors who purchased shares of Revance Therapeutics Inc (NASDAQ:RVNC) common stock in its June 19, 2014 follow-on public stock offering have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of Revance Therapeutics Inc (NASDAQ:RVNC) common stock in its June 19, 2014 follow-on public stock offering, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the Registration Statement issued in connection with the June 19, 2014 follow-on public stock offering allegedly failed to disclose, among other things, that Revance Therapeutics Inc had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014,and that Revance Therapeutics Inc did not have the quality or quantity of RT001 on hand sufficient to complete and successful Phase 3 clinical trial.

On June 19, 2014 Revance Therapeutics Inc announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $30.50 per share pursuant to a registration statement filed with the Securities and Exchange Commission ("SEC").

Shares of Revance Therapeutics Inc (NASDAQ:RVNC) grew to $33.56 per share on June 27, 2014 but declined over the next months to as low as $15.45 per share in October 2014, respectively $15.51 per share in November 2014.

Those who purchased shares of Revance Therapeutics Inc (NASDAQ:RVNC) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com